22 M
|
mRNA
BNT162B2
|
NS
|
13 days
|
54,921
|
NA
|
Methylprednisolone
Dexamethasone
Anakinra
IVIG
|
3
|
36 M
|
Vector
ChAdOx1 nCoV-19
|
NS
|
1 day
|
1482
|
NA
|
Methylprednisolone
|
8
|
36 F
|
mRNA
BNT162B2
|
NS
|
10 days
|
4312
|
NA
|
Methylprednisolone
Tocilizumab
|
9
|
53 M
|
Vector
ChAdOx1 nCoV-19
|
NS
|
10 weeks
|
3140
|
NA
|
Prednisone
|
10
|
20 F
|
Vector
ChAdOx1 nCoV-19
|
NS
|
10 days
|
11,491
|
NA
|
Naproxen
|
11
|
47 F
|
Vector
ChAdOx1 nCoV-19
|
NS
|
3 weeks
|
404
|
NA
|
Methotrexate
Tocilizumab
|
11
|
35 F
|
Vector
ChAdOx1 nCoV-19
|
NS
|
3 months
|
>100,000
|
NA
|
Methylprednisolone
|
11
|
59 F
|
mRNA
BNT162B2
|
NA
|
10 days
|
11,491
IL-18
|
≥5000
|
Methylprednisolone
Prednisolone
Tocilizumab
Cyclosporin
|
12
|
35 M |
mRNA-1273 |
NA |
24 days |
1263 |
NA |
Prednisolone |
12 |
65 M
|
Vector
ChAdOx1 nCoV-19
|
Psoriatic arthritis
|
1 day
|
1550
|
NA
|
Prednisone
Anakinra
|
13
|
50 F
|
mRNA
BNT162B2
|
UC
|
21 days
|
2383
|
131000
|
Loxoprofen
|
Our case
|